Mylan has finalized a $465M settlement with the U.S. DOJ and other government agencies over the classification of its EpiPen auto injectors in the Medicaid Drug Rebate Program
The ordeal continues.
For his 'Executive Decision' segment, Cramer again sat down with Joe Papa, chairman and CEO of Valeant
What's next for Valeant Pharmaceuticals shares?
Evercore ISI analyst Josh Schimmer is bullish on biotech.
A number of biotech-related stocks were down pre-market after announcing plans for public offerings.
Domestic politics take the spotlight yet again
Citigroup cut its rating for the struggling generic drug maker to 'neutral'.
Cramer's outlook on drug stocks.
Agilent turned in another stellar earnings results.